RxDoctor Payments Data

Priya Balakrishnan

Medical · Bedford, TXNPI 1528342342

Payments from drug & device makers

$4,071in general payments, 2019–2025

Across 140 payments — averaging $29.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Johnson & Johnson$266
  • 180 Medical, Inc.$248
  • Endo USA, Inc.$221
  • AbbVie$206
  • Sumitomo Pharma America, Inc.$193
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$98824%
  • Food & beverage$3,08376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,071 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$35,294
Medicare patients
211
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron306$242,151
GemtesaVibegron51$37,243
Mirabegron ErMirabegron42$18,958
Methenamine Hippurate259$15,508
PremarinEstrogens, Conjugated22$9,806
Solifenacin Succinate159$8,911
Tamsulosin Hcl447$5,304
Testosterone16$4,447
Oxybutynin Chloride ErOxybutynin Chloride185$4,413
Finasteride220$2,821
Tolterodine Tartrate ErTolterodine Tartrate25$2,341
Estradiol42$2,321
Cephalexin137$2,107
Desmopressin Acetate17$1,690
Silodosin18$1,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$122$242,151306 claims
Sumitomo Pharma America, Inc.Gemtesa$193$37,24351 claims
PfizerPremarin$42$9,80622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,490 medical providers in Texas.

Other medical in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →